Tag: Biotech

Hybrid biopharmaceutical manufacturing facilities that combine stainless steel (SSTs) and single-use (SUTs) technologies are the “sweet spot” from an environmental sustainability perspective, according to new research. The research compared the environmental impact—specifically, the carbon footprint— of hybrid facilities with those where SUTs are used, arguing that ongoing efforts to decarbonize energy generation may have shifted the metrics.

And the key findings are that the CO₂ footprint of SUTs is significantly higher than previously assumed and that key SST process steps can now have a lower carbon footprint than their single-use counterparts.

Lead author Jan Reiners, rer. nat. , from Roche, tells GEN, “For a long time, SUT was considered more sustainable because it avoids the energy needed to clean and steam-sterilize stainless steel. However, this paradigm has now inverted due to the rapid decarbonization worldwide due to the expansion of renewable energy.

“A single-use run at the 2,000L scale generates up to 6.5 tons of CO2e per batch only in plastic and packaging waste. We didn’t do this assessment for a full stainless-steel system, but the hybrid facility used less than half of plastics,” he adds.

Reiners and colleagues used “market-based emissions accounting” data for the analysis, noting it is becoming common for drug companies to decouple emissions from local energy supplies through tools like power purchase agreements and on-site photovoltaic (PV) installations.

“For instance, our own organization, Roche, has recently achieved its global goal of sourcing 100% sustainable electricity across all worldwide operations. And we are not alone: AstraZeneca is reducing energy emissions by 98% by 2026 and transitioning to 100% renewable energy for heat and power. Novartis claims to have become carbon neutral for energy in 2025, as do many other companies,” he says.

The researchers also found that some long-standing assumptions about SUT systems— for example, that they have lower HVAC costs—no longer hold.

“In modern biomanufacturing, cleanroom ISO classifications remain identical for both SUT and SST due to functionally closed processing, while the massive logistics and warehousing required to store SUT consumables actually expand physical space requirements,” continues Reiners. “And finally, the mass of fossil-fuel-based plastics was underestimated and its CO₂ impact actually increased by ~30% in updated global life cycle databases like Ecoinvent v3.12.”

Hybrid alternatives

Considering the findings, Reiners and co-authors suggest that, to minimize emissions and costs, biopharmaceutical manufacturers need to combine stainless-steel systems with SUTs.

“Although SUT is less sustainable, it has other advantages like faster product changeover, more flexibility, less investment, but higher running costs. A hybrid facility is the ‘sweet spot’ of combining SUT and stainless steel to reduce the CO₂ impact,” he maintains. “Depending on the facility layout, various measures can reduce the footprint, but per se it is about retaining stainless steel for simple, high-volume, resource-heavy operations—like buffer and media preparation—while keeping single-use for the complex, flexible core process like bioreactors.

“In our study, comparing a full-SUT facility to a hybrid facility reduced the material-related carbon footprint by 62%, dropping emissions from 6.5 tons of CO2e to just 2.8 tons of CO2e per batch.”

The post Hybrid Single-Use and Stainless-Steel Plants the Greener Option appeared first on GEN – Genetic Engineering and Biotechnology News.

Lonza and Engitix signed a licensing agreement to advance the development of antibody-drug conjugates (ADCs) as therapies for patients with chronic diseases.

Engitix will access Lonza’s ADC technology platform through a single-target license, including the use of SYNtecan E linker-payload and complementary GlycoConnect^® and HydraSpace^®. These technologies are intended to support Engitix’s goal to develop and commercialize therapies.

Lonza, through one of its affiliated companies, is eligible to receive upfront, clinical, regulatory, and commercial milestone payments, plus royalties on net sales of resulting products. Lonza is responsible for manufacturing components that are related to its proprietary technologies, and Engitix will work on the R&D, manufacturing, and commercialization of the ADCs.

Engitix has developed a proprietary human extracellular matrix (ECM) platform that allows the study of disease biology directly in human tissue, according to a company official, who adds that this approach focuses on targets within the ECM itself, offering a differentiated pathway compared to traditional methods that focus on cell surface targets. 

The collaboration enables Engitix to leverage Lonza’s established ADC technology platform to develop differentiated therapeutic candidates designed to selectively deliver potent payloads to tumor-selective targets identified through Engitix’s proprietary human ECM discovery platform, explains Giuseppe Mazza, MD, PhD, CEO and co-founder of Engitix.

‘We are committed to translating our unique understanding of the disease microenvironment into transformative therapies for patients with high unmet medical need,” he continues. “Licensing Lonza’s clinically validated conjugation and linker-payload technologies provides us with a powerful toolkit to develop next-generation ECM-targeted therapeutics with the potential for enhanced efficacy, reduced toxicity and improved therapeutic index.” 

“We are pleased to collaborate with Engitix on this innovative program,” says Jan Vertommen, vice president of commercial development, advanced synthesis, Lonza. “By combining our ADC development and  manufacturing expertise with Engitix’s unique ECM-based discovery platform, we aim to advance next-generation ADCs and unlock new possibilities in targeted therapies for patients.” 

The post Engitix Licenses Lonza’s Technology to Advance ADC Therapies appeared first on GEN – Genetic Engineering and Biotechnology News.